← ANALYSTS · TIPRANKS
Jay Olson · Oppenheimer
Hits
48%
236 of 492 ratings made money (TipRanks, all the analyst’s ratings)
Average return of a rating
+24.9%
Over a year after the rating, TipRanks’ measure
Our companies rated now
20
Buy / hold / sell: 20 / 0 / 0
Upside of the analyst’s targets
+280.5%
Average over 20 current targets, to the last price
The market’s answer to the ratings
+4.8%
Day-0 move against SPY in the rating’s direction, average over 10 upgrades, downgrades and target changes
| Date · added, NY | Stock | Action | Rating | Price target | Upside | Move vs SPY | |
|---|---|---|---|---|---|---|---|
| Oct 1on TipRanks 07:50 | SGMTIWMSagimet Biosciences, Inc. Class A · $575M | Reiterated | Buy | $33.00 → $38.00+15.2% | +373.8% | −5.3%next day −3.2% · 5 days −6.1% | ↗ |
| Sep 22on TipRanks 12:50 | VKTXViking Therapeutics · $3.4B | Assigned | Buy | $100 → $120+20.0% | +376.8% | +35.7%next day +2.7% · 5 days −20.9% | ↗ |
| Sep 14on TipRanks 16:05 | DFTXIWMDefinium Therapeutics · $4.6B | Reiterated | Buy | $70.00 → $75.00+7.1% | +133.6% | −8.1%next day +3.2% · 5 days +7.1% | ↗ |
| Aug 27on TipRanks 08:31 | ANLAdlai Nortye Ltd. Sponsored ADR · $701M | Reiterated | Buy | $32.00 | +190.1% | −5.6%next day −3.3% · 5 days +2.7% | ↗ |
| Aug 27on TipRanks 08:20 | RVMDRevolution Medicines · $41.5B | Reiterated | Buy | $230 → $260+13.0% | +46.1% | +2.0%next day −5.8% · 5 days −4.9% | ↗ |
| Aug 17on TipRanks Aug 18 05:55 | PRAXIWMPraxis Precision Medicines · $6.9B | Reiterated | Buy | $650 | +168.9% | +3.1%next day −1.1% · 5 days −1.0% | ↗ |
| Aug 12on TipRanks 08:15 | SGMTIWMSagimet Biosciences, Inc. Class A · $575M | Reiterated | Buy | $33.00 | +311.5% | −1.6%next day −1.9% · 5 days +13.1% | ↗ |
| Aug 6on TipRanks 09:01 | CHRSIWMCoherus Biosciences · $165M | Reiterated | Buy | $10.00 | +910.1% | −12.6%next day −0.2% · 5 days −11.1% | ↗ |
| Aug 6on TipRanks 09:01 | QTTBQ32 Bio · $246M | Reiterated | Buy | $40.00 | +431.9% | −1.6%next day −4.3% · 5 days −6.3% | ↗ |
| Aug 6on TipRanks 09:01 | BIOAIWMBioAge Labs, Inc. · $249M | Reiterated | Buy | $50.00 | +933.1% | +2.8%next day +3.4% · 5 days −8.7% | ↗ |
| Aug 5on TipRanks 08:35 | FTHFaeth Therapeutics · $517M | Reiterated | Buy | $60.00 | +219.1% | −3.4%next day −0.3% · 5 days +19.1% | ↗ |
| Aug 5on TipRanks 07:55 | AMGNQQQSPYAmgen · $235B | Reiterated | Buy | $400 → $450+12.5% | +4.0% | +4.8%next day −0.6% · 5 days +1.7% | ↗ |
| Jul 31on TipRanks 08:35 | NBIXNeurocrine · $13.9B | Reiterated | Buy | $230 | +69.5% | −10.8%next day −1.8% · 5 days −5.5% | ↗ |
| Jul 28on TipRanks 13:50 | INCYSPYIncyte · $23.0B | Reiterated | Buy | $107 → $120+12.1% | +6.1% | +9.1%next day −0.6% · 5 days −11.3% | ↗ |
| Jun 15on TipRanks 07:35 | ZNTLIWMZentalis Pharmaceuticals · $212M | Initiated | Buy | $9.00 | +322.5% | −1.0%next day −6.3% · 5 days −0.1% | ↗ |
| May 11on TipRanks 08:10 | DNLIIWMDenali Therapeutics · $2.9B | Reiterated | Buy | $35.00 → $40.00+14.3% | +127.1% | 0.0%next day −0.9% · 5 days −6.4% | ↗ |
| May 8on TipRanks 08:45 | NKTRIWMNektar Therapeutics · $1.3B | Reiterated | Buy | $140 | +291.3% | −2.6%next day −4.1% · 5 days −14.0% | ↗ |
| Apr 22on TipRanks 10:06 | HRMYIWMHarmony Biosciences Holdings · $2.2B | Reiterated | Buy | $62.00 → $72.00+16.1% | +89.7% | −1.5%next day +0.7% · 5 days −2.9% | ↗ |
| Mar 9on TipRanks Mar 10 03:50 | IMRXIWMImmuneering · $235M | Reiterated | Buy | $30.00 | +735.7% | +4.6%next day +0.2% · 5 days −10.4% | ↗ |
| Feb 9on TipRanks Feb 18 12:05 | MDGLMadrigal Pharmaceuticals · $10.4B | Reiterated | Buy | $650 | +44.5% | +1.8%next day −1.7% · 5 days +1.4% | |
| Nov 7on TipRanks 15:00 | NTLAIWMIntellia Therapeutics · $1.6B | Reiterated | Buy | $33.00 → $27.00−18.2% | +136.4% | −22.8%next day +0.6% · 5 days −8.8% | ↗ |
| No ratings for this filter. | |||||||
Ratings of the stocks the collector reads (the companies of QQQ, SPY, IWM, SMH, SOXL and SOXS and the other US stocks of TipRanks’ feed of new ratings) that it has kept: every new one since 30 September 2026, before that the analyst’s latest rating of each company. Upside is the target over the stock’s last price. The analyst at TipRanks ↗